Promising Results in 18-Month Analysis of Alzheimer Drug Candidate

The highest dose of BAN2401, an investigational drug for early Alzheimer disease, significantly slowed cognitive decline by 30% compared with placebo at 18 months, according to detailed results from a phase 2 randomized trial presented at the Alzheimer Association International Conference in July.